Targeting FGFR1 enhances olaparib sensitivity via MAPK-mediated BRCA2 downregulation in mCRPC
Together, these data reveal an <i>FGFR1</i>-driven, MAPK-dependent mechanism that sustains <i>BRCA2</i> and attenuates PARP-inhibitor activity, nominate <i>FGFR1</i> status as a candidate biomarker of PARP-inhibitor responsiveness, and support biomarker-guided co-targeting of FGFR1 and PARP in <i>BRCA2</i>-dependent mCRPC.
Authors
- Shaoyou Liu (ORCID: https://orcid.org/0000-0001-5544-1661)
- Weide Zhong (ORCID: https://orcid.org/0000-0002-0430-2845)
- Ziqing Zhou (ORCID: https://orcid.org/0000-0001-9600-2075)
- Jiarun Lai (ORCID: https://orcid.org/0009-0008-1886-5156)
- Rui Zhou (ORCID: https://orcid.org/0000-0001-5373-6917)
- Zhaodong Han
- Huichan He
- Yufeng Long (ORCID: https://orcid.org/0000-0001-8477-3884)
- Jiaming Su
- Jian Ping Chen (ORCID: https://orcid.org/0009-0003-6024-1906)
Institutions
- Macau University of Science and Technology (MO)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Women and Children Medical Center (CN)
- Guangdong Province Women and Children Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Translational Andrology and Urology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tau-2025-490
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00